A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors

A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors

Abstract Background Less than half of unselected metastatic cancer patients benefit from the immune checkpoint inhibitor (ICI) therapy. Systemic cancer-related inflammation may influence the efficacy of ICIs and thus, systemic inflammatory markers could have prognostic and/or predictive potential in...

Full description

Bibliographic Details
Main Authors: Satu Tiainen, Veera Nurmela, Tuomas Selander, Patrik Turunen, Sanna Pasonen-Seppänen, Tiia Kettunen, Outi Kuittinen, Päivi Auvinen, Aino Rönkä
Format: Article
Language:English
Published: BMC 2023-12-01
Series:BMC Cancer
Subjects:
Immune checkpoint inhibitor
ICI
Prognostic
Predictive
cancer
Inflammation
Online Access:https://doi.org/10.1186/s12885-023-11699-0

Internet

https://doi.org/10.1186/s12885-023-11699-0

Similar Items